|   In the News

Atlas seedling banks $35M to feel out the future of immuno-oncology

Checkpoint inhibitors, designed to help the immune system better identify and attack cancer, have become the consensus next big things in oncology. But startup Surface Oncology is looking beyond their transformative promise with eyes on the next generation of immunotherapies, chasing some newly identified targets and raising $35 million to get rolling.

Read more.


  |   LifeSciVC

Immuno-Oncology: Scratching the Surface

By Bruce Booth, DPhil, Partner

Another day, another announcement about great data from immuno-oncology. It’s clearly one of the hottest fields in biopharma today, and has been for a few years. Read more.


  |   Press Release

Intellia Therapeutics, Novartis Form Partnership to Develop New Cell Therapies Using CRISPR/Cas9 Technology

Intellia Therapeutics, a leader in the development of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, today announced a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs). This collaboration comes only three months after Intellia was launched by Atlas Venture and Caribou Biosciences, providing an important validation of Intellia’s team and capabilities.

Read more.


  |   In the News

Padlock banks $23M with a fresh approach to autoimmune disease

The majority of treatments for autoimmune diseases have a simple hypothesis: If the immune system is flaring up, attack its defenses and tamp it down. But startup Padlock Therapeutics has a novel approach it believes could cut in on the inflammatory process before things get so dire, and the biotech has $23 million in fresh cash to explore the idea. Read more.


  |   From the Trenches

Rekindling The Flame

I thought I was done with immunology. I’m not formally trained as an immunologist, but I fell for it hard back in graduate school, when immunology was leading the molecular biology revolution. Read more.